Treating psoriatic arthritis: how effective are TNF antagonists?
Treating psoriatic arthritis: how effective are TNF antagonists?
复制标题
DOI：
10.1186/ar1016
复制
发表时间：
2004-06-01
影响因子：
4.9
通讯作者：
Antoni, CE
中科院分区：
文献类型：
--
作者：
Gottlieb, AB;Antoni, CE
银屑病关节炎（PsA）是一种血清阴性的脊椎关节病，通常出现在特征性皮肤病变发病后。该并发症影响约40%的中度至重度皮肤病患者。PsA患者的滑液和组织分析显示，肿瘤坏死因子（TNF）和其他细胞因子水平较高，与类风湿关节炎（RA）患者相似。在过去，这种疾病的医疗管理包括使用非甾体抗炎药治疗。病情更严重的患者已经尝试了许多不同的疾病缓解药物，包括甲氨蝶呤、硫唑嘌呤和金盐。然而，没有证据表明这些药物可以阻止结构关节损伤的进展。英夫利昔单抗和依那西普是TNF拮抗剂，已证明对RA患者有显著的疗效和安全性。这两种药物在PsA患者中的临床试验显示，该疾病的风湿病学和皮肤表现有显著改善。
Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy that commonly appears after the onset of the characteristic cutaneous lesions. This complication affects about 40% of patients with moderate to severe cutaneous disease, Analysis of synovial fluid and tissue in patients with PsA demonstrates a profile of high levels of tumor necrosis factor (TNF) plus other cytokines similar to those seen in patients with rheumatoid arthritis (RA). In the past, medical management of patients with this disease consisted of treatment with nonsteroidal anti-inflammatory agents. Patients with more severe disease have tried a number of different disease-modifying drugs including methotrexate, azathioprine, and gold salts. However, there is no evidence that these agents can arrest the progress of structural joint damage. Infliximab and etanercept are TNF antagonists that have demonstrated significant efficacy and safety in patients with RA. Clinical trials with these two agents in patients with PsA have shown significant improvement in the rheumatologic and cutaneous manifestations of the disease.